Merit Medical Systems, Inc. MMSI R2K
Company Overview
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Why Investors Should Care
Net profit has compounded at 11.5% per year over the last five years.
Revenue has grown at a 11.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.52B (+11.8% YoY); net profit $128.49M.
- Trailing 12 Months Year-on-year growth — revenue +7.5%, earnings +38.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.7%, profit CAGR 11.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.72% |
| 1 Year: | 7.50% |
Compounded Profit Growth
| 5 Years: | 11.50% |
| 1 Year: | 38.80% |
Stock Price Performance
| 1 Year: | -24.00% |
| 6 Months: | -17.78% |
| 3 Months: | +0.64% |
| 1 Month: | +6.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.20 · Neutral
P/E of 30.61 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.7% over 5 years.
- Profit CAGR of 11.5% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MMSI Merit Medical Systems, Inc. R2K | 71.02 | 30.61 | $4.24B | 0.00% | 7.55% | 9.12% | 11.72% | 11.50% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 171.07M | 186.55M | 179.34M | 190.90M | 203.03M | 224.81M | 221.66M | 233.25M | 238.35M | 255.53M | 243.05M | 257.92M | 243.53M | 218.37M | 243.97M | 258.00M | 248.91M | 280.32M | 267.02M | 275.42M | 294.98M | 287.18M | 297.56M | 320.06M | 315.23M | 323.51M | 338.00M | 339.85M | 355.35M | 382.46M | 384.16M | 381.88M |
| Gross Profit | 55.38M | 60.89M | 59.20M | 60.31M | 60.10M | 66.85M | 67.81M | 70.26M | 75.94M | 84.14M | 80.51M | 85.66M | 88.06M | 100.01M | 102.04M | 104.67M | 104.64M | 111.96M | 104.14M | 111.63M | 103.78M | 84.22M | 102.01M | 111.16M | 111.89M | 124.14M | 120.49M | 120.91M | 135.07M | 128.57M | 138.36M | 152.78M | 142.20M | 151.72M | 161.10M | 157.53M | 172.02M | 184.49M | 186.41M | 184.80M |
| Operating Income | 8.70M | 12.24M | 8.55M | - | 7.71M | 11.58M | 2.99M | 12.60M | 5.61M | 13.36M | 879.00K | 13.22M | 8.78M | 15.11M | 21.06M | 13.66M | 9.52M | 12.20M | -2.88M | -3.41M | 1.36M | -19.00M | 64.00K | 16.01M | 14.19M | 8.89M | 15.93M | 15.23M | 23.26M | 18.66M | 26.38M | 28.81M | 35.14M | 35.92M | 45.95M | 37.26M | 41.03M | 46.88M | 42.61M | 44.16M |
| Net Income | 5.17M | 7.40M | 4.82M | 6.41M | 4.35M | 7.29M | 973.00K | 7.51M | 14.80M | 9.48M | -3.57M | 6.81M | 5.27M | 10.94M | 16.62M | 9.19M | 6.20M | 6.86M | -3.40M | -4.21M | -3.15M | -19.06M | -3.01M | 15.38M | 10.96M | 4.92M | 11.97M | 10.54M | 15.30M | 15.27M | 20.70M | 20.25M | 25.83M | 28.24M | 35.73M | 28.44M | 30.15M | 32.58M | 27.75M | 40.99M |
| Diluted EPS | 0.12 | 0.17 | 0.11 | 0.14 | 0.10 | 0.16 | 0.02 | 0.17 | 0.32 | 0.19 | -0.07 | 0.13 | 0.10 | 0.21 | 0.30 | 0.16 | 0.11 | 0.12 | -0.06 | -0.08 | -0.06 | -0.34 | -0.05 | 0.27 | 0.19 | 0.09 | 0.21 | 0.18 | 0.27 | 0.27 | 0.36 | 0.35 | 0.44 | 0.48 | 0.61 | 0.48 | 0.49 | 0.54 | 0.46 | 0.68 |
| R&D Expense | 9.67M | 9.20M | 10.52M | - | 10.59M | 11.43M | 11.42M | - | 12.53M | 13.31M | 12.84M | - | 14.32M | 15.32M | 14.53M | - | 16.04M | 16.33M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 257.46M | 296.75M | 359.45M | 394.29M | 449.05M | 509.69M | 542.15M | 603.84M | 727.85M | 882.75M | 994.85M | 963.88M | 1.07B | 1.15B | 1.26B | 1.36B | 1.52B |
| Gross Profit | 108.80M | 128.50M | 165.47M | 181.99M | 194.37M | 225.22M | 235.78M | 265.02M | 326.25M | 394.77M | 432.37M | 401.18M | 485.33M | 519.10M | 583.87M | 643.33M | 738.27M |
| Operating Income | 32.85M | 17.20M | 33.19M | 29.64M | 27.84M | 40.17M | 37.54M | 34.88M | 33.07M | 58.62M | 15.43M | -1.56M | 60.92M | 87.56M | 123.94M | 155.69M | 184.72M |
| Net Income | 22.53M | 12.46M | 23.04M | 19.71M | 16.57M | 22.97M | 23.80M | 20.12M | 27.52M | 42.02M | 5.45M | -9.84M | 48.45M | 74.52M | 94.41M | 120.36M | 128.49M |
| Diluted EPS | 0.63 | 0.35 | 0.58 | 0.46 | 0.39 | 0.53 | 0.53 | 0.45 | 0.55 | 0.78 | 0.10 | -0.18 | 0.84 | 1.29 | 1.62 | 2.03 | 2.13 |
| R&D Expense | 11.17M | 15.34M | 21.94M | 27.80M | 33.89M | 36.63M | 40.81M | 45.23M | 51.40M | 59.53M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 271.51M | 369.48M | 447.02M | 705.31M | 728.28M | 747.16M | 778.73M | 942.80M | 1.11B | 1.62B | 1.76B | 1.66B | 1.65B | 1.66B | 2.33B | 2.42B | 2.69B |
| Total Equity | 194.31M | 218.81M | 235.62M | 357.09M | 381.58M | 405.71M | 435.26M | 466.10M | 498.19M | 676.33M | 932.77M | 949.94M | 958.58M | 1.04B | 1.14B | 1.20B | 1.38B | 1.58B |
| Cash & Equivalents | 34.03M | 6.13M | 3.73M | 10.13M | 9.72M | 7.46M | 7.36M | 4.18M | 19.17M | 32.34M | 67.36M | 44.32M | 56.92M | 67.75M | 58.41M | 587.04M | 376.71M | 446.40M |
| Long Term Debt | - | - | 81.54M | 30.74M | 227.57M | 238.85M | 214.49M | 197.59M | 314.37M | 259.01M | 373.15M | 431.98M | 343.72M | 234.40M | 186.76M | 823.01M | 729.55M | 734.04M |
| Total Liabilities | - | - | 133.87M | 89.93M | 323.73M | 322.58M | 311.91M | 312.62M | 444.61M | 435.48M | 687.24M | 807.38M | 705.82M | 608.50M | 519.57M | 1.12B | 1.04B | 1.10B |
| Current Liabilities | - | - | 40.18M | 43.80M | 73.00M | 65.59M | 75.43M | 87.91M | 88.33M | 115.62M | 175.34M | 181.66M | 185.00M | 236.28M | 220.65M | 203.56M | 216.40M | 239.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 30.07M | 34.76M | 34.02M | 46.94M | 51.37M | 53.33M | 69.46M | 53.60M | 62.73M | 86.53M | 77.81M | 165.27M | 147.23M | 114.29M | 145.15M | 220.80M | 297.37M |
| Investing Cash Flow | -65.79M | -112.83M | -74.02M | -255.57M | -68.61M | -36.20M | -62.02M | -159.11M | -146.76M | -378.82M | -134.48M | -58.65M | -37.16M | -57.40M | -175.35M | -368.65M | -247.39M |
| Financing Cash Flow | 7.82M | 76.12M | 46.70M | 208.29M | 14.77M | -16.97M | -10.23M | 121.09M | 96.52M | 328.28M | 33.53M | -95.71M | -98.44M | -60.26M | 559.27M | -60.01M | 16.00M |
| Capital Expenditure | -18.48M | -23.65M | -59.20M | -64.64M | -59.51M | -34.18M | -50.96M | -32.84M | -38.62M | -63.32M | -78.17M | -45.99M | -27.94M | -45.03M | -34.29M | -35.14M | -81.72M |
| Free Cash Flow | 11.59M | 11.11M | -25.18M | -17.70M | -8.13M | 19.14M | 18.50M | 20.76M | 24.10M | 23.21M | -360.00K | 119.28M | 119.29M | 69.26M | 110.86M | 185.66M | 215.66M |
| Share Buybacks | 2.47M | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 42.3% | 43.3% | 46.0% | 46.2% | 43.3% | 44.2% | 43.5% | 43.9% | 44.8% | 44.7% | 43.5% | 41.6% | 45.2% | 45.1% | 46.4% | 47.4% | 48.7% |
| Operating Margin % | 12.8% | 5.8% | 9.2% | 7.5% | 6.2% | 7.9% | 6.9% | 5.8% | 4.5% | 6.6% | 1.6% | -0.2% | 5.7% | 7.6% | 9.9% | 11.5% | 12.2% |
| Net Margin % | 8.8% | 4.2% | 6.4% | 5.0% | 3.7% | 4.5% | 4.4% | 3.3% | 3.8% | 4.8% | 0.5% | -1.0% | 4.5% | 6.5% | 7.5% | 8.9% | 8.5% |
| ROE % | 10.3% | 5.3% | 6.5% | 5.2% | 4.1% | 5.3% | 5.1% | 4.0% | 4.1% | 4.5% | 0.6% | -1.0% | 4.7% | 6.5% | 7.9% | 8.7% | 8.1% |
| ROCE % | - | 5.2% | 8.2% | 4.7% | 4.2% | 6.0% | 5.4% | 4.1% | 3.3% | 4.1% | 1.0% | -0.1% | 4.3% | 6.1% | 5.8% | 7.1% | 7.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.81% | 8.83M | $629.75M |
| 2 | Vanguard Portfolio Management LLC | 5.91% | 3.52M | $251.14M |
| 3 | Vanguard Capital Management LLC | 4.45% | 2.66M | $189.34M |
| 4 | State Street Corporation | 3.96% | 2.36M | $168.30M |
| 5 | Conestoga Capital Advisors, LLC | 3.63% | 2.17M | $154.51M |
| 6 | Fuller & Thaler Asset Management Inc. | 3.55% | 2.12M | $150.81M |
| 7 | Geode Capital Management, LLC | 2.53% | 1.51M | $107.52M |
| 8 | Morgan Stanley | 2.11% | 1.26M | $89.89M |
| 9 | Dimensional Fund Advisors LP | 2.07% | 1.24M | $88.20M |
| 10 | Nomura Asset Management International Inc | 2.01% | 1.20M | $85.42M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MMSI
Is Merit Medical Systems Inc (MMSI) a Bargain After 3.1% Drop? GF Value Says Undervalued - GuruFocus
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQN1dvVDBqZ3o3d25uMXhVbUFIcFBIMWlfcTJGS0tNbE9rRkYwNHNHNjAwQ25XaFNtTjlTUWw4elFjUEdJZjZEdnByNDVYMW5pdkVPWGhwNXpubnhqUXF3YnRxekNCeEZjRVpqSGgxS3A4MHNYYUtDX2ZwOExWaTBwcTh5OHJPX1FsalZYcE…
Merit Medical Systems, Inc. (MMSI) Stock Analysis: A 21.93% Upside Potential Beckons Investors - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPbUt1NFRUV3pRSV9ONXM5UzdFcUd2ZXduQmdWYm42Wk5PcjVwT1otYkNZaF9UR0prVlhSWVZjbDU3cUpaNElJM1lHOEk4NmptV3JmaFg5QTNtcGJ5ZWtxUU5WTEhwenN6SUR4RTFOMGRqVnR3WVZsaE9tYVhiU3RMdVVpdGl5TExyWjA0ZE…
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNdU5yalRKdDJKa2dseDYxc3Q2UDV0b1FZV1Nnb1BhU3pWY2phLU4yLTZCb0tteThGbFpIcUh6YnJnck43Zmxydy10ZGI2dVh4bHc0TTdDWWo0dUZjNFJ2VVNQbnBLY2ZaRFhscWw5WURmcWRydkFfbWlIWEQ2SG1jRXZEajJoOERlZGhtbz…
Merit Medical Systems Inc (NASDAQ:MMSI): A Quality Investing Analysis - ChartMill
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPazJWMllOcjRSWDZ5cUZqd3poVUNUbS1xeFdVTzY5YkxyQjR4cTcxOXpNWTRUa2NBRHp6MjNRNGo1T0plWWxSQTlnNVVrY1BRY1BXWXBGeG12UmFZNHNKdHVoU3cxSzV0V05GX01SSmZmamNrbEpIbEJ1TUQ1YzFtemVNRTJUdWlQQlVaT3…
Merit Medical schedules July 30 results and investor call - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbjl4ZjdybnVhdlMtTkRDbDlFTk56OERrcXdoY29TYzF4ZDk1V0RtSnNvNnd5VUtnWU1GLWVlZlJtT1lKQnp0RVRNNS1WUnVnODBBdjdJdW1BUnhqZWxHUExhODRfWXh6M2U5WEowR1lNZHJTb2tyeWpEUURCLUpYTDR1a2ZXVG9ibVhGcH…
Merit Medical Systems (MMSI) Could Be 21% Below Fair Value Following Splashwire Recall - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNLU8tM1Z5THBLOW5WLUltS3lwd1VIbDhlSUFGR1dVVFhKYVdnMXBIdm1NWWhETTl2MHY2V1lTSFFHT0ZrYl9mSC0xZEFjY2xLd0dYaC1JUVF3OG4wa0R5MFh4RXRfSjh1MVI2Q2Y3Nkl1djdVVGhPbHFjOHBaMnBqSTcxTEtEMS1TakJxYj…
MMSI — Frequently Asked Questions
What is the current share price of Merit Medical Systems, Inc. (MMSI)?
As of 2026-07-14 21:23 PDT, Merit Medical Systems, Inc. (MMSI) trades at $71.02 on NasdaqGS. Its 52-week range is $60.31 to $93.60.
What is the market capitalisation of MMSI?
Merit Medical Systems, Inc. (MMSI) has a market capitalisation of $4.24B on NasdaqGS.
What is the P/E ratio of MMSI?
MMSI trades at a trailing price-to-earnings (P/E) ratio of 30.61. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.44.
What is the return on equity (ROE) of MMSI?
MMSI has a return on equity (ROE) of 9.12%. Its return on capital employed (ROCE) is 7.55%.
Is MMSI a good stock to buy?
This page provides a data-driven analysis of Merit Medical Systems, Inc. (MMSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.